- Home
- EMN vs MIRM Comparison
EMN vs MIRM Comparison
Compare EMN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EMN | MIRM |
|---|---|---|
| Founded | 1920 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.2B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EMN | MIRM |
|---|---|---|
| Price | $62.46 | $82.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | $76.19 | ★ $153.07 |
| AVG Volume (30 Days) | ★ 1.2M | 766.8K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $8,752,000,000.00 | $19,138,000.00 |
| Revenue This Year | $5.62 | $33.62 |
| Revenue Next Year | $1.88 | $17.72 |
| P/E Ratio | $24.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.11 | $63.23 |
| 52 Week High | $83.47 | $130.00 |
Technical Indicators
Market Signals| Indicator | EMN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 36.04 | 41.12 |
| Support Level | $62.13 | $77.78 |
| Resistance Level | $70.42 | $88.31 |
| Average True Range (ATR) | 1.53 | 3.86 |
| MACD | 0.04 | 0.31 |
| Stochastic Oscillator | 10.71 | 39.16 |
Price Performance
Historical ComparisonAbout EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.